stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.13
0.77
+4.44%
Follow DYN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 53 | 53 | 267 | +123.4% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (5) | (15) | (59) | (149) | (168) | (236) | (317) | (446) | (519) | +91.0% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (5) | (15) | (59) | (149) | (168) | (236) | (317) | (446) | (519) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.11) | (6.08) | (4.13) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) | (3.33) | +63.7% | ||||||
| Cash flow | — | — | (0.09) | (4.84) | (3.23) | (2.35) | (2.96) | (3.15) | (3.11) | (3.14) | (2.89) | +65.7% | ||||||
| Capex | — | — | 0.00 | (0.67) | (0.08) | (0.07) | (0.06) | (0.01) | (0.03) | (0.01) | (0.02) | n/m | ||||||
| Free cash flow | — | — | (0.09) | (5.52) | (3.31) | (2.42) | (3.02) | (3.16) | (3.13) | (3.15) | (2.90) | +65.8% | ||||||
| Book value | — | — | 0.09 | 5.75 | 23.78 | 7.23 | 4.86 | 1.53 | 6.69 | 7.57 | 4.24 | +87.7% | ||||||
| Shares, m | — | — | 45 | 2 | 14 | 51 | 52 | 60 | 94 | 128 | 150 | +16.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (4) | (12) | (47) | (120) | (154) | (188) | (292) | (403) | (478) | +92.2% | |||||
| Capex | — | — | 0 | (2) | (1) | (4) | (3) | (1) | (2) | (2) | (3) | +46.3% | ||||||
| Free cash flow | — | — | (4) | (13) | (48) | (123) | (157) | (189) | (295) | (405) | (480) | +92.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 7 | 12 | 338 | 354 | 238 | 78 | 617 | 1,076 | 860 | +103.5% | |||||
| Net debt | — | — | (5) | (15) | (345) | (348) | (230) | (123) | (642) | (962) | (685) | +113.5% | ||||||
| Shareholders’ equity | — | — | 4 | 14 | 342 | 368 | 252 | 91 | 630 | 972 | 702 | +117.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (116.38) | (120.30) | (32.15) | (38.33) | (45.93) | (100.10) | (74.14) | (47.52) | (60.29) | +68.9 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (460.33) | (480.77) | 0.00 | 0.00 | (2,790.00) | (1,956.27) | (2,790.0) pt | ||||||
| ROE | — | — | 52.66 | 162.64 | (36.13) | (42.02) | (54.18) | (137.31) | (88.03) | (55.71) | (81.57) | (108.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 47 | 95 | 123 | 141 | 191 | 258 | — | +40.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Dyne Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $3.7B | 10.0× | 33.4× | +22.85% (above 0%: growing) | −27.91% (below 0%: shrinking) | +141.15% (above 0%: growing) | 89.75% | 20.95% | Compare |
| TARS Tarsus Pharmaceuticals, Inc. | $3.3B | — (loss-making) | — (loss-making) | +63.92% (above 0%: growing) | n/m | −144.14% (below 0%: shrinking) | 92.86% | (340.29%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −47.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ELVN Enliven Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DYN Dyne Therapeutics, Inc. | $3.2B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | |
| VRDN Viridian Therapeutics, Inc. | $3.2B | — (loss-making) | — (loss-making) | −63.51% (below 0%: shrinking) | n/m | −9.92% (below 0%: shrinking) | 100.00% | (401.82%) | Compare |
| TLX Telix Pharmaceuticals Limited | $3.2B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | Compare |
| DNLI Denali Therapeutics Inc. | $3.2B | — (loss-making) | — (loss-making) | −93.96% (below 0%: shrinking) | n/m | −11.83% (below 0%: shrinking) | 98.92% | (712.97%) | Compare |
| CELC Celcuity, Inc. | $3.1B | — (loss-making) | — | — | n/m | −53.27% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.3B | — | — | −20.33% | — | −28.30% | 89.75% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
9.46%
Entities affiliated with T. Rowe Price Investment Management, Inc.
15.93%
Entities affiliated with Janus Henderson Group plc
8.32%
Jason Rhodes
5.55%
Entities affiliated with Atlas Venture Fund XI, L.P.
5.47%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement